$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2019 Form 10-K Financial Statement

#000164033420000582 Filed on March 23, 2020

Income Statement

Concept	2019	2018 Q4	2018
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.395M	$1.080M	$4.363M
YoY Change	0.73%	17.39%	22.96%
% of Gross Profit
Research & Development	$2.238M	$240.0K	$330.0K
YoY Change	578.24%	242.86%	6.0%
% of Gross Profit
Depreciation & Amortization	$1.462K	$0.00	$1.544K
YoY Change	-5.31%		-80.8%
% of Gross Profit
Operating Expenses	$6.633M	$1.320M	$4.693M
YoY Change	41.34%	33.33%	21.59%
Operating Profit	-$6.633M		-$4.693M
YoY Change	41.34%
Interest Expense	$1.001M	-$4.910M	$94.76K
YoY Change	956.02%	-1463.89%	-87.64%
% of Operating Profit
Other Income/Expense, Net	$7.686M		-$14.50M
YoY Change	-153.01%
Pretax Income	$1.053M	-$6.220M	-$19.19M
YoY Change	-105.49%	887.3%	520.58%
Income Tax	$1.600K	$0.00	$1.642K
% Of Pretax Income	0.15%
Net Earnings	$1.052M	-$6.220M	-$19.19M
YoY Change	-105.48%	547.92%	520.31%
Net Earnings / Revenue
Basic Earnings Per Share	$0.01		-$0.16
Diluted Earnings Per Share	-$0.05	-$11.73	-$0.16
COMMON SHARES
Basic Shares Outstanding	135.2M shares		121.2M shares
Diluted Shares Outstanding	169.6M shares		121.2M shares

Balance Sheet

Concept	2019	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.830M	$1.850M	$1.853M
YoY Change	-1.26%	611.54%	612.94%
Cash & Equivalents	$1.830M	$1.853M	$1.853M
Short-Term Investments
Other Short-Term Assets	$164.8K	$2.609K	$100.3K
YoY Change	64.28%	-99.1%	-66.1%
Inventory
Prepaid Expenses		$93.19K
Receivables
Other Receivables
Total Short-Term Assets	$1.995M	$1.954M	$1.954M
YoY Change	2.1%	248.87%	251.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.980K	$3.445K	$3.450K
YoY Change	-42.61%		144.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.980K	$3.445K	$3.440K
YoY Change	-42.44%		143.97%
TOTAL ASSETS
Total Short-Term Assets	$1.995M	$1.954M	$1.954M
Total Long-Term Assets	$1.980K	$3.445K	$3.440K
Total Assets	$1.997M	$1.957M	$1.957M
YoY Change	2.02%	249.49%	251.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$139.8K	$15.60K	$15.60K
YoY Change	796.22%	-84.4%	-84.54%
Accrued Expenses		$180.0K	$184.5K
YoY Change		-10.0%	-7.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$970.8K	$15.94M	$15.94M
YoY Change	-93.91%	1867.77%	1877.61%
LONG-TERM LIABILITIES
Long-Term Debt	$387.1K	$1.360M	$1.361M
YoY Change	-71.56%
Other Long-Term Liabilities	$90.80K	$220.0K	$219.5K
YoY Change	-58.62%	-60.0%	-60.2%
Total Long-Term Liabilities	$477.9K	$1.580M	$1.580M
YoY Change	-69.76%	186.58%	186.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$970.8K	$15.94M	$15.94M
Total Long-Term Liabilities	$477.9K	$1.580M	$1.580M
Total Liabilities	$1.449M	$17.52M	$17.52M
YoY Change	-91.73%	1188.19%	1190.75%
SHAREHOLDERS EQUITY
Retained Earnings		-$33.23M
YoY Change
Common Stock		$17.66M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$548.1K	-$15.56M	-$15.56M
YoY Change
Total Liabilities & Shareholders Equity	$1.997M	$1.957M	$1.957M
YoY Change	2.02%	249.49%	251.23%

Cashflow Statement

Concept	2019	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	$1.052M	-$6.220M	-$19.19M
YoY Change	-105.48%	547.92%	520.31%
Depreciation, Depletion And Amortization	$1.462K	$0.00	$1.544K
YoY Change	-5.31%		-80.8%
Cash From Operating Activities	-$6.028M	-$1.010M	-$3.943M
YoY Change	52.88%	-52.13%	18.36%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$4.385K
YoY Change	-100.0%	-100.0%	-122.32%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$4.385K
YoY Change	-100.0%	-100.0%	-77.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.919M		$3.096M
YoY Change	-38.0%		2.75%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.005M	1.810M	$5.541M
YoY Change	8.37%	-23.95%	57.73%
NET CHANGE
Cash From Operating Activities	-$6.028M	-1.010M	-$3.943M
Cash From Investing Activities	0.000	0.000	-$4.385K
Cash From Financing Activities	$6.005M	1.810M	$5.541M
Net Change In Cash	-$23.37K	800.0K	$1.594M
YoY Change	-101.47%	220.0%	883.28%
FREE CASH FLOW
Cash From Operating Activities	-$6.028M	-$1.010M	-$3.943M
Capital Expenditures	$0.00	$0.00	$4.385K
Free Cash Flow	-$6.028M	-$1.010M	-$3.947M
YoY Change	52.71%	-52.58%	19.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001516551
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	us-gaap	Cash Cash	667000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1983	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3445	USD
CY2019Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	10000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	271715	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	551322	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4538	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4512	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	152695	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	970818	USD
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018Q4	us-gaap	Cash Cash	1853373	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15938971	USD
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Entity Registrant Name EntityRegistrantName	Emerald Bioscience, Inc.
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	17116620	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	183207747	shares
CY2019Q4	us-gaap	Cash Cash	1829977	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	93193	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7550	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2609	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1994760	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1953687	USD
CY2019Q4	us-gaap	Assets Assets	1996743	USD
CY2018Q4	us-gaap	Assets Assets	1957132	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	129809	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15597	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	420406	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	184461	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	410603	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15738913	USD
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	182895247	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	133907747	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	182895247	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	133907747	shares
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17528947	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-3569506	USD
CY2019	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-9734759	USD
CY2018	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	6503174	USD
CY2019	embi	Fair Value Of Derivative Liability In Excess Of Proceeds FairValueOfDerivativeLiabilityInExcessOfProceeds	-322644	USD
CY2018	embi	Fair Value Of Derivative Liability In Excess Of Proceeds FairValueOfDerivativeLiabilityInExcessOfProceeds	-7174634	USD
CY2018	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	-137192	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7686003	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14500071	USD
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135154931	shares
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-803	USD
CY2019	embi	Fair Value Of Derivative Liability Excess Of Proceeds FairValueOfDerivativeLiabilityExcessOfProceeds	322644	USD
CY2018	embi	Fair Value Of Derivative Liability Excess Of Proceeds FairValueOfDerivativeLiabilityExcessOfProceeds	7174634	USD
CY2018	embi	Loss On Common Stock Issuance From Conversion Of Accrued Interest LossOnCommonStockIssuanceFromConversionOfAccruedInterest	9794	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	10000	USD
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	225945	USD
CY2018	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-10110	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4385	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4385	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	80628	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	154092	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	400000	USD
CY2019	embi	Proceeds From Convertible Multi Draw Credit Agreement ProceedsFromConvertibleMultiDrawCreditAgreement	3990699	USD
CY2018	embi	Proceeds From Convertible Multi Draw Credit Agreement ProceedsFromConvertibleMultiDrawCreditAgreement	1946293	USD
CY2019	embi	Repayment Of Convertible Multi Draw Credit Agreement RepaymentOfConvertibleMultiDrawCreditAgreement	3985500	USD
CY2018	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1947228	USD
CY2018	embi	Conversion Of Outstanding Preferred Stock Subject To Redemption Into Common Stock ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock	828915	USD
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1713766	USD
CY2018	embi	Fair Value Of Warrants Issued In Connection With Financings FairValueOfWarrantsIssuedInConnectionWithFinancings	10424634	USD
CY2019	embi	Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement	716110	USD
CY2018	embi	Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement	315080	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32173282	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33225107	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	548058	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-15562252	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1996743	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1957132	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2237956	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	329966	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4394622	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4362557	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	6632578	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	4692523	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-6632578	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-4692523	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-725425	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-590392	USD
CY2019	us-gaap	Interest Expense InterestExpense	1000713	USD
CY2018	us-gaap	Interest Expense InterestExpense	94763	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	26	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	84	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1053425	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19192594	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1642	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	1051825	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-19194236	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	680455	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	674961	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9734759	USD
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121154334	shares
CY2019	us-gaap	Depreciation Depreciation	1462	USD
CY2018	us-gaap	Depreciation Depreciation	1544	USD
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121154334	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	169560265	shares
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6503174	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	629293	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	58536	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	59502	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-198235	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	4941	USD
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2609	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	124212	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-85324	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6027941	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3943014	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1919372	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3095908	USD
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4080000	USD
CY2018	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	98700	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6004571	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5540901	USD
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-23370	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1593502	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1857885	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264383	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1834515	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	371420	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	23334	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	1642	USD
CY2019	embi	Exercise Of Warrants ExerciseOfWarrants	6077698	USD
CY2018	embi	Exercise Of Warrants ExerciseOfWarrants	1539866	USD
CY2019	embi	Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	716110	USD
CY2018	embi	Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	90080	USD
CY2019	embi	Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	1584850	USD
CY2019	embi	Share And Warrants Issuance Costs ShareAndWarrantsIssuanceCosts	80628	USD
CY2019	embi	Stock Issued During Period Value Net Of Issuance Costs And Warrants StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants	1919372	USD
CY2019	embi	Financing Value Warrant Exercise FinancingValueWarrantExercise	10013323	USD
CY2019	embi	Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement	193414	USD
CY2018	embi	Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement	204102	USD
CY2019	embi	Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement	1584850	USD
CY2018	embi	Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement	90080	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	674961	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	680455	USD
CY2018	embi	Share Issuance Costs ShareIssuanceCosts	16900	USD
CY2018	embi	Stock Issued During Period Value Net Of Issuance Costs StockIssuedDuringPeriodValueNetOfIssuanceCosts	-16900	USD
CY2018	embi	Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock Value ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue	828915	USD
CY2018	embi	Conversion Of Series D Preferred Stock To Common Stock ConversionOfSeriesDPreferredStockToCommonStock	169447	USD
CY2018	embi	Conversion Of Series F Preferred Stock To Common Stock Value ConversionOfSeriesFPreferredStockToCommonStockValue	1777781	USD
CY2018	embi	Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest	1723560	USD
CY2018	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	1638566	USD
CY2019	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	144375	USD
CY2018	embi	Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	315080	USD
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Use of Estimates</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify"> </p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities and debt with embedded features.</span></span></span></span></span></span></span></span></span></span></span></span></p></div>
CY2017Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	823037	USD
CY2018	embi	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	-2356581	USD
CY2019	embi	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	516058	USD
CY2018	embi	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	10988736	USD
CY2019	embi	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	-6238265	USD
CY2019Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	1877938	USD
CY2018Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	3176824	USD
CY2019	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line method
CY2019	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	two to three years
CY2019	embi	Warrants Vested And Outstanding WarrantsVestedAndOutstanding	25143250	shares
CY2018Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	15958366	USD
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	501400	USD
CY2019	embi	Coupon Interest Expense CouponInterestExpense	371420	USD
CY2018	embi	Coupon Interest Expense CouponInterestExpense	26433	USD
CY2019	embi	Amortization Of Debt Discount AmortizationOfDebtDiscount	616383	USD
CY2018	embi	Amortization Of Debt Discount AmortizationOfDebtDiscount	56253	USD
CY2019	embi	Amortization Of Transaction Costs AmortizationOfTransactionCosts	12910	USD
CY2018	embi	Amortization Of Transaction Costs AmortizationOfTransactionCosts	2283	USD
CY2019	us-gaap	Interest Expense Other InterestExpenseOther	0	USD
CY2018	us-gaap	Interest Expense Other InterestExpenseOther	9794	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1051825	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19194236	USD
CY2019	embi	Net Loss Adjusted Balance NetLossAdjustedBalance	-8198787	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1120521	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-19192594	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1351	USD
CY2019Q4	embi	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	0	USD
CY2018Q4	embi	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	10327	USD
CY2019Q4	embi	Deferred Tax Liabilities Note Discount DeferredTaxLiabilitiesNoteDiscount	340652	USD
CY2018Q4	embi	Deferred Tax Liabilities Note Discount DeferredTaxLiabilitiesNoteDiscount	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019	embi	Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant	-1874873	USD
CY2018	embi	Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant	2869116	USD
CY2019	embi	Income Tax Reconciliation Uncertain Tax Positions IncomeTaxReconciliationUncertainTaxPositions	436145	USD
CY2018	embi	Income Tax Reconciliation Uncertain Tax Positions IncomeTaxReconciliationUncertainTaxPositions	0	USD
CY2019	embi	Income Tax Reconciliation Change In Compound Derivative IncomeTaxReconciliationChangeInCompoundDerivative	-101671	USD
CY2018	embi	Income Tax Reconciliation Change In Compound Derivative IncomeTaxReconciliationChangeInCompoundDerivative	3224	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	629	USD
CY2019Q4	embi	Annual Maintenance Fee Payable AnnualMaintenanceFeePayable	75000	USD

Files In Submission

Name	View Source	Status
0001640334-20-000582-index-headers.html	Edgar Link	pending
0001640334-20-000582-index.html	Edgar Link	pending
0001640334-20-000582.txt	Edgar Link	pending
0001640334-20-000582-xbrl.zip	Edgar Link	pending
embi-20191231.xml	Edgar Link	completed
embi-20191231.xsd	Edgar Link	pending
embi-20191231_cal.xml	Edgar Link	unprocessable
embi-20191231_def.xml	Edgar Link	unprocessable
embi-20191231_lab.xml	Edgar Link	unprocessable
embi-20191231_pre.xml	Edgar Link	unprocessable
embi_10k.htm	Edgar Link	pending
embi_ex231.htm	Edgar Link	pending
embi_ex311.htm	Edgar Link	pending
embi_ex312.htm	Edgar Link	pending
embi_ex321.htm	Edgar Link	pending
embi_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2019 Form 10-K Financial Statement

#000164033420000582 Filed on March 23, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2019 Form 10-K Financial Statement

#000164033420000582 Filed on March 23, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye